GLP-1 medications are prescription drugs, and any changes to your treatment plan should be discussed with your healthcare provider
As a pastor, finding the right church management system software was crucial for streamlining our operations
Your testosterone has a schedule, and it's running your life more than you realize
Theres a quieter signal of how seriously Lilly takes the long game: it sued the FDA in 2024 over whether retatrutide counts as a biologic, a classification worth billions because it would extend Lillys pricing power and block competitors for years
Formula: Large peptide sequence
Research goals: Metabolic & Weight Description Retatrutide (development code LY3437943) is a synthetic, once-weekly triple agonist of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors that has been the subject of peer-reviewed phase 1 and phase 2 randomized controlled trials published in The New England Journal of Medicine , The Lancet , and Nature Medicine , including investigations of body weight, glycemic control, and hepatic steatosis in adult human participants
